相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction
Marco Trevisan et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato et al.
LANCET (2021)
Long COVID - metabolic risk factors and novel therapeutic management
Kamlesh Khunti et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
Ofri Mosenzon et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock et al.
LANCET (2021)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik et al.
LANCET (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)
Juhani Knuuti et al.
EUROPEAN HEART JOURNAL (2020)
Effects of glucagon-tike peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
Fabio Marsico et al.
EUROPEAN HEART JOURNAL (2020)
Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial
Jie Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management
Anca Pantea Stoian et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2020)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Theo Vos et al.
LANCET (2020)
Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019
Christopher J. L. Murray et al.
LANCET (2020)
Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019 Update From the GBD 2019 Study
Gregory A. Roth et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Endogenous glucagon-like peptide-1 system response is impaired during ST-elevation myocardial infarction in type 2 diabetes patients
Gabby Elbaz-Greener et al.
DIABETES OBESITY & METABOLISM (2019)
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
Natasha C. Bergmann et al.
DIABETOLOGIA (2019)
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Jens Juul Holst
FRONTIERS IN ENDOCRINOLOGY (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial
Christian Anholm et al.
ATHEROSCLEROSIS (2019)
Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice
Kunduziayi Aini et al.
INTERNATIONAL HEART JOURNAL (2019)
The Global Burden of Cardiovascular Diseases and Risk Factors 2020 and Beyond
George A. Mensah et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction
John R. Ussher et al.
CELL METABOLISM (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation
Florian Kahles et al.
MOLECULAR METABOLISM (2018)
Recent updates on GLP-1 agonists: Current advancements & challenges
Dilip Sharma et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity
Sebastian Diebold et al.
DIABETES OBESITY & METABOLISM (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice
Yusaku Mori et al.
ENDOCRINOLOGY (2018)
Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies
Mathieu Boniol et al.
DIABETES CARE (2018)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus
Christophe Schmitt et al.
DIABETES OBESITY & METABOLISM (2017)
Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB
Lisa M. Berglund et al.
DIABETES (2016)
Sitagliptin decreases ventricular arrhythmias by attenuated glucose-dependent insulinotropic polypeptide (GIP)-dependent resistin signalling in infarcted rats
Tsung-Ming Lee et al.
BIOSCIENCE REPORTS (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
Michael A. Nauck et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
Manfredi Rizzo et al.
CARDIOVASCULAR DIABETOLOGY (2014)
GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6-Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering
Florian Kahles et al.
DIABETES (2014)
Cardiovascular disease in Europe 2014: epidemiological update
Melanie Nichols et al.
EUROPEAN HEART JOURNAL (2014)
Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease
Christine Bernsmeier et al.
PLOS ONE (2014)
Cardioprotective Effects of Exenatide in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Results of Exenatide Myocardial Protection in Revascularization Study
Jong Shin Woo et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe-/- mice
Mathias Burgmaier et al.
ATHEROSCLEROSIS (2013)
Adipose Dipeptidyl Peptidase-4 and Obesity Correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro
Henrike Sell et al.
DIABETES CARE (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Incretin hormone glucagon-like peptide-1 is increased in patients with acute-phase ST-elevation myocardial infarction treated with a primary percutaneous coronary intervention: a pilot study
Alex Blatt et al.
CARDIOVASCULAR ENDOCRINOLOGY (2013)
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Jacob Lonborg et al.
EUROPEAN HEART JOURNAL (2012)
Inflammation in atherosclerosis: a cause or a result of vascular disorders?
Ileana Manduteanu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Exenatide Exerts a Potent Antiinflammatory Effect
Ajay Chaudhuri et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice
Michishige Terasaki et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice
Yukinori Nogi et al.
PLOS ONE (2012)
Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
Zubair Shah et al.
CIRCULATION (2011)
Administration of an acylated GLP-I and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity
Victor A. Gault et al.
CLINICAL SCIENCE (2011)
GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
Nikolaos Mentis et al.
DIABETES (2011)
The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an Endothelial Resistance to Glucagon-Like Peptide 1 in Diabetes
Antonio Ceriello et al.
DIABETES CARE (2011)
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
M. Nagashima et al.
DIABETOLOGIA (2011)
Type 2 diabetes across generations: from pathophysiology to prevention and management
Christopher J. Nolan et al.
LANCET (2011)
One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress
Mathijs C. Bunck et al.
ATHEROSCLEROSIS (2010)
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Masayuki Arakawa et al.
DIABETES (2010)
Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
Juris J. Meier et al.
DIABETES (2010)
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Daniel J. Drucker et al.
DIABETES CARE (2010)
Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes
C. Daousi et al.
CLINICAL ENDOCRINOLOGY (2009)
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
K. B. Hansen et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Leo Timmers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice
Nigel Irwin et al.
REGULATORY PEPTIDES (2009)
The role of CD26/dipeptidyl peptidase IV in cancer
Pamela A. Havre et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice:: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide
Nigel Irwin et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice
Nigel Irwin et al.
JOURNAL OF PEPTIDE SCIENCE (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Effects of glucose-dependent insulinotropic peptide on osteoclast function
Qing Zhong et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
A. Barnett
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Management of Type 2 diabetes: the role of incretin mimetics
Anthony H. Stonehouse et al.
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts
Tingcun Zhao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor
R Ugleholdt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes
VA Gault et al.
DIABETES (2005)
The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway
CR Abbott et al.
BRAIN RESEARCH (2005)
Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation
J Nyberg et al.
JOURNAL OF NEUROSCIENCE (2005)
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
AK Bose et al.
DIABETES (2005)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
JP Gutzwiller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect
RL Prigeon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2003)
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
MJ During et al.
NATURE MEDICINE (2003)
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
M Yu et al.
JOURNAL OF HYPERTENSION (2003)
A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line
FM Gribble et al.
DIABETES (2003)
The influence of GLP-1 on glucose-stimulated insulin secretion -: Effects on β-cell sensitivity in type 2 and nondiabetic subjects
LL Kjems et al.
DIABETES (2003)
Glucose-sensing in glucagon-like peptide-1-secreting cells
F Reimann et al.
DIABETES (2002)
Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4
T Perry et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Reduced postprandial concentrations of intact biologically active gluccagon-like peptide 1 in type 2 diabetic patients
T Vilsboll et al.
DIABETES (2001)
Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain
JG Canto et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes
A Vella et al.
DIABETES (2000)
分享论文
